Home/Filings/4/0000950170-24-024222
4//SEC Filing

SMITH WAYNE T 4

Accession 0000950170-24-024222

CIK 0001108109other

Filed

Feb 29, 7:00 PM ET

Accepted

Mar 1, 7:52 PM ET

Size

26.6 KB

Accession

0000950170-24-024222

Insider Transaction Report

Form 4
Period: 2024-03-01
SMITH WAYNE T
DirectorChairman, President & CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2024-03-01+144,0005,227,075 total
  • Exercise/Conversion

    Performance Based Restricted

    2024-03-01144,00036,000 total
    Exercise: $0.00Common Stock (144,000 underlying)
  • Award

    Restricted Stock Units

    2024-03-01$2.87/sh+92,334$264,99992,334 total
    Exercise: $0.00Common Stock (92,334 underlying)
  • Disposition to Issuer

    Performance Based Restricted

    2024-03-0136,0000 total
    Exercise: $0.00Common Stock (36,000 underlying)
  • Award

    Restricted Stock Units

    2024-03-01$2.87/sh+62,718$180,00162,718 total
    Exercise: $0.00Common Stock (62,718 underlying)
Holdings
  • Restricted Stock Units

    Exercise: $0.00Common Stock (29,268 underlying)
    29,268
  • Stock Options (Right to Buy)

    Exercise: $4.93From: 2021-03-01Exp: 2030-02-28Common Stock (112,500 underlying)
    112,500
  • Stock Options (Right to Buy)

    Exercise: $8.81From: 2022-03-01Exp: 2031-02-28Common Stock (90,000 underlying)
    90,000
  • Stock Options (Right to Buy)

    Exercise: $10.18From: 2023-03-01Exp: 2032-02-29Common Stock (90,000 underlying)
    90,000
  • Stock Units (SU)

    Exercise: $0.00Common Stock (35,609.301 underlying)
    35,609.301
  • Common Stock

    (indirect: By Trust)
    1,606,842
  • Common Stock

    (indirect: By LLC)
    481,721
  • Performance Based Restricted

    Exercise: $0.00Common Stock (180,000 underlying)
    180,000
  • Restricted Stock Units

    Exercise: $0.00Common Stock (43,089 underlying)
    43,089
  • Stock Options (Right to Buy)

    Exercise: $4.99From: 2020-03-01Exp: 2029-02-28Common Stock (78,750 underlying)
    78,750
Footnotes (6)
  • [F1]The vesting of these 180,000 performance-based restricted shares was based on the attainment of certain performance objectives between 1/1/2021 and 12/31/2023 (the "2021-2023 Performance Period"). Based on the actual level of achievement of such performance objectives for the 2021-2023 Performance Period, the award vested on March 1, 2024 at 80% of the target number of the performance-based restricted shares originally reported by the Reporting Person on 3/2/2021 (144,000), and the remaining 20% of the target number has been forfeited (36,000).
  • [F2]The restricted stock units vest in 1/3 increments on the first, second and third anniversary of the date of grant. Based on the Reporting Person's prior deferral election pursuant to the terms of the award agreement, the Reporting Person will be issued that number of shares of common stock of the Company upon the Reporting Person's cessation as a director or upon a date specified by the Reporting Person.
  • [F3]The restricted stock units, which were granted as payment of the Reporting Person's additional annual stipend for serving as the Chair of the Board, vest in 1/3 increments on the first, second and third anniversary of the date of grant. Based on the Reporting Person's prior deferral election pursuant to the terms of the award agreement, the Reporting Person will be issued that number of shares of common stock of the Company upon the Reporting Person's cessation as a director or upon a date specified by the Reporting Person.
  • [F4]The vesting of these performance-based restricted shares is subject to the attainment of certain performance objectives between 1/1/2022 and 12/31/2024 (the "2022-2024 Performance Period"). The target number (100%) of the total performance-based restricted shares is reported in the table set forth above. Between 0% and 200% of the portion of the target number of performance-based restricted shares allocated to each applicable performance objective will ultimately vest on the third anniversary of the date of grant, subject to the attainment of the applicable performance objective, with the vesting percentage to be determined based upon the level of achievement with respect to the applicable performance objective during the 2022-2024 Performance Period.
  • [F5]Vesting occurs in 1/3 increments on the first, second and third anniversary of the date of grant.
  • [F6]The Stock Units were accrued under the Company's Directors' Fees Deferral Plan in lieu of a portion of the Reporting Person's Director Fees and are settled 100% in the Company's common stock on the last business day of the calendar quarter following cessation as a director or upon a date specified by the Reporting Person.

Documents

1 file

Issuer

COMMUNITY HEALTH SYSTEMS INC

CIK 0001108109

Entity typeother

Related Parties

1
  • filerCIK 0001018660

Filing Metadata

Form type
4
Filed
Feb 29, 7:00 PM ET
Accepted
Mar 1, 7:52 PM ET
Size
26.6 KB